What etherna immunotherapies does

etherna immunotherapies NV is a Belgium-based, privately held platform biotechnology company founded in 2013 as a spin-off from Vrije Universiteit Brussel (VUB). Headquartered in Niel with discovery operations in Ghent and a commercial presence in Boston, etherna develops proprietary messenger RNA (mRNA) chemistry and lipid nanoparticle (LNP) delivery technologies for nucleic acid-based therapeutics. The company rebranded from eTheRNA Immunotherapies to etherna in October 2023 as it pivoted from internal immunotherapy development toward a partnership-driven platform model under permanent CEO Bernard Sagaert and Chairman Tony de Fougerolles (former founding CSO of Moderna).

etherna's core technology assets include a proprietary library of more than 2,500 distinct ionizable lipids and six specialized LNP platforms — IV delivery for genetic diseases and gene editing, T-cell delivery for immuno-oncology and autoimmune disease, Liver LNP for repeat-dose hepatic expression, Tolerizing LNPs, the iVAX intramuscular vaccine platform, and an Intratumoral platform. The mRNA platform adds proprietary 5' and 3' UTR optimization, codon optimization algorithms, and CleanCap capping. A 2025 breakthrough is the Bio-Reducible LNP platform, which achieves mRNA expression in over 90% of mouse bone marrow hematopoietic stem and progenitor cells (HSPCs), representing a step-change in extrahepatic delivery. Manufacturing is supported by a cGMP-accredited facility in Niel, certified since 2018, with over 30 years of cumulative RNA manufacturing experience.

The business model is partnership-driven and multi-revenue-stream. etherna licenses its mRNA and LNP platforms to pharmaceutical and biotech partners (technology partnering) and co-develops proprietary therapeutic programs (product partnering), generating upfront payments, research funding, development and commercial milestones, and tiered royalties. Notable agreements include up to USD 950 million in potential milestones from Dropshot Therapeutics (cardiac and renal) and up to €300 million from Almirall (dermatology). A GMP manufacturing services business supplies cGMP RNA batches (minimum ~500mg) with CMC regulatory support to clinical-stage programs, and a webshop sells catalog research-grade mRNAs (eGFP, FLuc, HA, hEPO, Ova, LacZ, mCherry) from 100µg to over 50mg to academic and industrial customers. The company also participates in the WHO/MPP mRNA Technology Transfer Program supporting Afrigen Biologics in developing the first African-owned mRNA COVID-19 vaccine.

Name

etherna immunotherapies

Legal name

eTheRNA immunotherapies NV

Website

https://etherna.be

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

101–250 employees

Short description

etherna is a Belgium-based platform biotech developing proprietary mRNA chemistry and lipid nanoparticle (LNP) delivery technologies, partnering with pharmaceutical and biotech companies to co-develop nucleic acid therapeutics from discovery through GMP manufacturing.

Ownership category

akta.pro rank

Product category

Nucleic Acid Therapeutics / mRNA-LNP Technology Platform

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics) (HLAAADAG)

akta.pro secondary industries

RNA Delivery Technologies (LNPs, polymers, conjugates incl. GalNAc, peptides, exosomes) (HLAAADAD), mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA) (HLAGAGAC), mRNA Therapeutics (vaccines, protein replacement, immuno-oncology) (HLAAADAA), RNA Chemistry & Oligonucleotide Engineering (backbones, modifications, stereochemistry) (HLAAADAE)

Keywords

• MRNA therapeutics
• Lipid nanoparticles
• RNA-LNP delivery
• Nucleic acid medicines
• GMP RNA manufacturing

Headquarters

HQ city

Niel

HQ country

Belgium

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Technology Licensing and Platform Access: etherna licenses its proprietary mRNA chemistry and LNP delivery platforms to pharmaceutical and biotech partners through technology partnering agreements. Partners gain access to customizable lipid nanoparticles and advanced mRNA chemistry in exchange for upfront payments, technology access fees, and ongoing royalties on commercialized products.
2. GMP RNA Manufacturing Services: etherna provides full-range RNA production services from research grade through GMP for partners at all project stages, including process optimization, QC method development, GMP production, stability studies, and CMC regulatory support. Revenue is generated through service fees for manufacturing batches, with minimum quantities of approximately 500mg in clean room environments.
3. Research Grade mRNA Products: Sale of off-the-shelf catalog mRNA products (eGFP, FLuc, HA, hEPO, Ova, LacZ, mCherry) and custom research-grade mRNA synthesis. RNA is available from 100µg to gram scale with short delivery times. Revenue is generated through product sales with pricing based on quantity and customization level.
4. Milestone Payments: Through co-development partnerships, etherna receives upfront payments, research funding, and success-based development and commercial milestone payments. Notable agreements include up to USD 950 million potential from Dropshot Therapeutics and up to €300 million from Almirall, contingent on development and commercial success of multiple products.
5. Royalties on Commercial Sales: Tiered royalties based on future global sales of products developed under partnership agreements, generating ongoing revenue as partner products reach commercialization. Royalties are structured as a percentage of sales with tiered rates based on sales volumes.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

etherna immunotherapies is a clinical-stage biotechnology company that designs and supplies proprietary mRNA chemistries and application-tuned lipid nanoparticle (LNP) delivery platforms for nucleic-acid-based therapeutics. The company licenses and co-develops its RNA-LNP technology with pharmaceutical and biotechnology partners, and operates an integrated offering spanning RNA sequence design, LNP formulation, and GMP manufacturing for clinical supply.

Product overview

etherna is a platform-driven RNA-LNP technology company offering integrated capabilities across RNA chemistry, LNP formulation, and Process Technology. The product portfolio consists of multiple LNP platforms (IV Delivery for genetic diseases/gene editing, T-cell LNP for immuno-oncology, Liver LNP for hepatic expression, Tolerizing LNP for autoimmune diseases, iVAX for prophylactic vaccines, and Intratumoral LNP for cancer immunotherapy), an mRNA Platform for sequence optimization and RNA production, and RNA products (Catalog RNAs, Research Grade RNA, GMP Grade RNA). Services include Technology Partnering for platform access, Product Partnering for therapeutic co-development, and Platform-Integrated Manufacturing. The company operates from research grade through GMP manufacturing in its Belgian facilities.

Differentiator

Problem solved

Functional benefit

Products and services

• IV Delivery LNP Platform (Genetic Diseases & Gene Editing)

Quantifiable outcome

• At least 5-fold improvement in mRNA expression over clinical benchmark LNPs for vaccine applications in NHP studies
• +5 more outcomes

Named customers9 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Nine partnerships are on record, tiered core and flagship.

• Dropshot TherapeuticscoreStrategic or Co-development Partner · 9 January 2025Strategic multi-target collaboration combining etherna's mRNA and LNP platforms with Dropshot's cardiac and renal disease biology expertise. The partnership aims to create multiple novel proprietary RNA-based therapeutics and advance them rapidly from preclinical to clinical stages. etherna receives an upfront payment, research funding, and milestone payments potentially worth up to USD 950 million, plus tiered royalties on commercial sales. Dropshot is co-founded by Kenneth R. Chien (Moderna co-founder) and Marijn E. Dekkers (former CEO of Bayer and Thermo Fisher), and is based near Boston, USA.
• VIB-VUB (Vlaams Instituut voor Biotechnology and Vrije Universiteit Brussel)coreStrategic or Co-development Partner · 10 December 2024Collaborative research leading to publication in Nature Communications demonstrating therapeutic potential of etherna's intratumoral mRNA-LNP platform. The study showed 85% tumor regression in triple-negative breast cancer models using a Triplet combination of IL-21, IL-7, and 4-1BBL mRNAs. The collaboration leverages VIB-VUB's tumor immunology research alongside etherna's mRNA and LNP technology platforms.
• Universiteit Gent (UGent)coreStrategic or Co-development Partner · 10 December 2024Research collaboration partner alongside VIB-VUB in the preclinical cancer immunotherapy study published in Nature Communications, contributing immunology and oncology expertise to the development of etherna's mRNA-LNP intratumoral immunotherapy platform.
• Hasselt UniversitycoreStrategic or Co-development Partner · 21 May 2024Research collaboration funded by a €1.7 million Flanders Innovation & Entrepreneurship (VLAIO) grant. The project aims to develop a tolerizing mRNA-LNP platform that restores immune homeostasis for deployment across autoimmune diseases, with a particular focus on multiple sclerosis. Combines etherna's mRNA and LNP technologies with UHasselt's immunology expertise through the Biomedical Research Institute (BIOMED).
• AlmirallcoreStrategic or Co-development Partner · 12 December 2023Multi-target alliance for developing mRNA-based therapies for severe skin diseases including non-melanoma skin cancer. The collaboration leverages etherna's proprietary mRNA and LNP technology with Almirall's medical dermatology expertise. etherna receives upfront and technology access payments, with potential milestone payments of up to €300 million plus tiered royalties contingent on launch and commercial success of multiple products. Almirall leads clinical development and commercialization. A therapy candidate LAD116 has been nominated and is advancing to IND-enabling studies and Phase I clinical trials.
• Afrigen BiologicsflagshipStrategic or Co-development Partner · 25 March 2023Expert development partner supporting Afrigen in developing the first African-owned mRNA COVID-19 vaccine under the WHO/MPP mRNA Technology Transfer Program. etherna provides proprietary lipid technology, thermostable vaccine platform, and LNP formulation expertise to enable manufacturing that can operate in standard refrigeration conditions suitable for low- and middle-income countries. This collaboration was highlighted during a royal visit by HM King Philippe and HM Queen Mathilde of Belgium.
• Univercells / Quantoom BiosciencesflagshipStrategic or Co-development Partner · 1 June 2021Supporting the development of the first African-owned mRNA COVID-19 vaccine as part of the WHO/MPP mRNA Technology Transfer Program. Univercells' Quantoom Biosciences leads mRNA production technology development (Ntensify midi system), while etherna provides proprietary lipids and formulation expertise. The partnership aims to establish distributed vaccine manufacturing capability in Africa and LMICs.
• VIB (Vlaams Instituut voor Biotechnology)coreStrategic or Co-development PartnerLong-standing research collaboration with VIB's researchers at Vrije Universiteit Brussel on mRNA-LNP cancer immunotherapy. Joint work published in Nature Communications demonstrating 85% tumor regression in preclinical cancer models using etherna's mRNA-LNP Triplet immunotherapy platform.
• Medicines Patent Pool (MPP)flagshipStrategic or Co-development PartnerCo-leader with WHO of the mRNA Technology Transfer Program. MPP collaborates with technology partners including etherna to facilitate technology transfer and manufacturing capacity building in LMICs for mRNA vaccines.

Scale indicators11 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• BioNTech: Global mRNA therapeutics leader with deep LNP expertise and integrated mRNA design, manufacturing, and commercialization capabilities. Directly comparable to etherna in mRNA-LNP platform technology, though BioNTech operates at vastly larger scale across a broader therapeutic footprint.
• Moderna: The most prominent commercial-stage mRNA company, with proprietary LNP technology and end-to-end capabilities from design through commercial manufacturing. Several etherna leaders (Tony de Fougerolles as founding CSO, Kenneth Chien as co-founder) came from Moderna, making it a natural benchmark for platform strategy and scale.
• Translate Bio (Sanofi): mRNA therapeutics company acquired by Sanofi in 2021, focused on vaccines and protein replacement. Directly comparable in mRNA platform focus, though now operating as part of Sanofi's broader portfolio rather than as a standalone platform partner.

Direct peers

• CureVac: Germany-based mRNA therapeutics company developing prophylactic vaccines and oncology therapies, with proprietary RNA optimization and GMP manufacturing. Closely comparable to etherna in technology focus (mRNA platform, GMP manufacturing) and European base, though CureVac is publicly listed and larger.
• Arcturus Therapeutics: Clinical-stage mRNA medicines company with proprietary LUNAR LNP delivery platform and STARR mRNA technology. Directly comparable to etherna in offering a platform-based mRNA-LNP solution with multiple partnered programs, including vaccines and rare disease therapeutics.
• Acuitas Therapeutics: Private Canadian company specializing in lipid nanoparticle delivery systems for mRNA therapeutics, notably the LNP technology used in Comirnaty (Pfizer-BioNTech COVID-19 vaccine). The closest pure-play LNP delivery peer to etherna, competing for pharma partnerships across mRNA programs.
• Genevant Sciences: Lipid nanoparticle delivery technology company focused on nucleic acid therapeutics, with a library of ionizable and neutral lipids comparable to etherna's 2,500+ lipid library. Competes directly for pharma LNP licensing and co-development partnerships.

Emerging players

• Strand Therapeutics: Clinical-stage synthetic biology company developing self-replicating mRNA therapeutics for oncology and other diseases. Comparable to etherna as an emerging platform-based mRNA company, with a more focused product portfolio but similar partnering-driven business model.
• Aldevron (Danaher): CDMO providing plasmid DNA, mRNA, and recombinant proteins for therapeutic developers. Comparable to etherna's GMP RNA manufacturing services business, with broader biologics manufacturing capabilities; now part of Danaher's Cytiva life sciences platform.
• Quantoom Biosciences (Univercells): Belgian mRNA CDMO and technology developer partnering with etherna on the WHO mRNA Technology Transfer Program. Comparable as a mid-stage mRNA manufacturing and technology platform player, with focused mid-scale production equipment rather than full therapeutic pipeline.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/etherna-immunotherapeutics

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Funding overview

Funding rounds5 records

Investors13 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about etherna immunotherapies